Home Lexicon Announces Focus On Late-Stage Development Programs And Preparation For Commercialization
 

Keywords :   


Lexicon Announces Focus On Late-Stage Development Programs And Preparation For Commercialization

2014-02-05 07:12:10| drugdiscoveryonline News Articles

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today it is focusing its resources on its late-stage drug development programs, principally LX4211 for diabetes and telotristat etiprate (LX1032) for carcinoid syndrome, and preparation for the transition to commercialization

Tags: development focus programs preparation

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
25.06Atlantic Tropical Weather Outlook
25.06Eastern North Pacific Tropical Weather Outlook
25.06Will there be more air travel chaos this summer?
25.06Bankruptcy trustee plans to shut down Alex Jones' Infowars
25.06Eastern North Pacific Tropical Weather Outlook
25.06Atlantic Tropical Weather Outlook
25.06The screen tech that can do almost anything
25.06Criminal charges recommended against Boeing
More »